Understanding Prostate Cancer

Prostate cancer develops in the prostate gland, a walnut-sized organ that sits below the bladder and produces seminal fluid. It is the second most common cancer among Indian men, with incidence rising steadily as life expectancy increases. Many men live for years with prostate cancer without knowing it, as early-stage disease often causes no symptoms. When detected early through PSA screening or after symptoms develop, outcomes improve significantly with timely intervention.

The disease varies dramatically in behavior. Some prostate cancers grow so slowly they never threaten life; others become aggressive and spread to bones or lymph nodes. This variability means one man might safely watch his cancer with active surveillance, while another needs immediate surgery or radiation. Choosing the right path depends on your age, Gleason score, PSA level, and overall health. Modern medicine now has multiple effective approaches that allow you to live well even after diagnosis.

Treatment has evolved beyond surgery and external beam radiation. Today’s toolkit includes hormonal therapies, chemotherapy, targeted nuclear medicine (Lu-177 PSMA), and PARP inhibitors for specific mutations. Indian patients benefit from increasingly accessible generic medications, bringing costs down while maintaining efficacy. Your oncology team will tailor therapy based on your cancer’s behavior and your life goals — whether that means aggressive treatment for cure or careful monitoring to preserve quality of life.

Types of Prostate Cancer

10 Warning Signs of Prostate Cancer

1. Urinary hesitancy: Difficulty starting or stopping urinary stream. Weak or interrupted flow.
2. Urinary frequency: Frequent urination, especially at night (nocturia). May wake 3-4 times nightly.
3. Hematuria: Blood in urine or semen. Usually painless but alarming when noticed.
4. Pelvic discomfort: Pain or heaviness in lower abdomen, perineum, or rectum during or after ejaculation.
5. Erectile dysfunction: Difficulty achieving or maintaining erection. May appear years before other symptoms.
6. Bone pain: Pain in lower back, hips, or pelvis — sign of metastatic spread to skeleton. Constant, worse at night.
7. Unexplained weight loss: Loss of >5 kg over months without diet change. Indicates advanced disease or hormonal therapy side effects.
8. Fatigue: Persistent tiredness despite adequate sleep. Common with advanced cancer or androgen deprivation therapy.
9. Lymph node swelling: Enlarged lymph nodes in groin or abdomen found on imaging. Suggests regional spread.
10. No symptoms: Many men have no signs at all. Cancer found incidentally during PSA screening or imaging for other reasons.

If you notice any of these, see a doctor. In most cases the cause turns out to be benign, but the only way to be sure is an evaluation.

Who Is at Risk?

How We Diagnose Prostate Cancer

Staging & Prognostic Risk Groups (TNM staging (AJCC 8th Edition) + Gleason score guide stage assignment. Stage I (T1, Gleason &#8804;6, PSA <10) carries excellent prognosis; Stage IV (any T, any N, M1 or PSA >40) indicates metastatic disease.)

Treatment Options

Active Surveillance

When used: Very low–risk and low-risk localized disease. Men with ≤10-year life expectancy.

Regular PSA checks (every 3–6 months), DRE (annual), and repeat biopsy (at 1–2 years, then as needed) without immediate treatment. Allows cancer to remain untreated if indolent.

Effectiveness: Excellent for truly low-risk disease. ~30% of men require treatment over 10 years. Delays side effects of surgery/radiation.

Side effects: Psychological burden of ‘living with cancer.’ Small risk (2–5%) cancer becomes aggressive before caught. Requires patient compliance and trust.

Cost in India: ₹2,000–3,500 per surveillance round (PSA – DRE – imaging as needed). Over 10 years: ₹20,000–40,000 if no progression.

Robot-Assisted Radical Prostatectomy (RARP)

When used: Localized disease (T1–T3a), all risk groups if candidate. Preferred if ≤65 years or >10-year life expectancy and node-negative.

Robot (da Vinci) enables magnified 3D visualization and precise dissection. Entire prostate, seminal vesicles, and surrounding fascia removed. Pelvic lymph node dissection added if intermediate–high risk. Nerve-sparing technique attempted when safe.

Effectiveness: Curative intent in localized disease. PSA recurrence-free survival: 85% – 10 years (low-risk), 70–75% (intermediate), 50–60% (high-risk). ~70% retain continence and ~40% retain erectile function with bilateral nerve sparing.

Side effects: Urinary incontinence (mild: 10–15%, severe: <2%). Erectile dysfunction (50–70% without function; <20% with nerve sparing). Stricture (5%), bleeding (<1%), infection (<1%).

Cost in India: ₹4,00,000–8,00,000 depending on hospital tier and complexity. Pelvic lymph node dissection adds ₹1,00,000.

External Beam Radiation Therapy (EBRT)

When used: All risk groups with localized disease. Preferred if >70 years, high surgical risk, or patient preference.

Intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) delivers conformal radiation. Typical dose 78–80 Gy over 8–9 weeks. Pelvic lymph nodes included if intermediate–high risk.

Effectiveness: Curative intent. PSA recurrence-free survival: 85% (low-risk), 70–75% (intermediate), 50–60% (high-risk) at 10 years. Hypofractionation (higher dose fewer fractions) increasingly used.

Side effects: Acute: urinary frequency/dysuria (20%), rectal symptoms (15%). Late (>3 months): erectile dysfunction (30–50%), rectal bleeding/diarrhea (5%), urinary incontinence (2–5%). Risk rises with dose and time.

Cost in India: ₹2,00,000–4,00,000 for full course. Simulation – planning – 39 treatments over 8 weeks.

Brachytherapy (Seed Implant)

When used: Low–intermediate risk localized disease. High dose rate (HDR) brachytherapy less common, used for high-risk with EBRT.

Radioactive seeds (Iodine-125, Palladium-103) implanted directly into prostate under ultrasound guidance. Seeds deliver high dose to prostate over months while sparing rectum/bladder.

Effectiveness: Excellent local control in low-risk disease. 15-year PSA recurrence-free survival: 85–90% (low-risk). Fewer long-term rectal/erectile toxicities than EBRT.

Side effects: Acute: urinary retention (10–15%), dysuria (20%), rectal discomfort (5%). Late: erectile dysfunction (30–40%), urinary stricture (5%). Lower rectal toxicity than EBRT.

Cost in India: ₹3,00,000–5,00,000 for full implant with post-plan and follow-up dosimetry.

Androgen Deprivation Therapy (ADT) – Hormonal

When used: Intermediate–very high risk localized (with EBRT), all metastatic disease. Duration 6 months (intermediate), 24–36 months (high/very high), indefinite (metastatic).

Prostate cancer depends on androgen signaling. GnRH agonists (leuprolide, goserelin, buserelin) suppress testosterone. First-generation agents: bicalutamide (150 mg), flutamide. Second-generation: enzalutamide, abiraterone, apalutamide block AR directly or CYP17 enzyme.

Effectiveness: ADT alone: PSA nadir at 4–6 weeks; testosterone suppressed <50 ng/dL within 2–4 weeks. Median time to PSA progression: 18–24 months. Adds 2–5 years median survival in hormone-sensitive disease. Second-gen agents delay resistance by 12–18 months vs first-gen.

Side effects: Hot flashes (70%), erectile dysfunction (100%), decreased libido, weight gain (mean +4–6 kg), muscle loss, gynecomastia/breast tenderness, osteoporosis (5-year fracture risk 15–20%), mood changes, metabolic syndrome.

Cost in India: GnRH agonist: ₹3,000–5,000/month. First-gen AR antagonist: ₹1,500–3,000/month. Second-gen: ₹8,000–35,000/month depending on agent. Long-term ADT can cost ₹2,00,000+ per year.

• leuprolide: GnRH agonist. Dose: 7.5 mg IM monthly or 22.5 mg IM 3-monthly. Onset 1 week. Cost ₹3,000–5,000 per injection.
• goserelin: GnRH agonist implant. Dose: 3.6 mg SC monthly or 10.8 mg SC 3-monthly. Cost ₹8,000–12,000 per implant.
• bicalutamide: First-gen AR antagonist. Dose: 150 mg daily. Cost ₹1,500–3,000/month. Used with GnRH agonist to block flare.
• enzalutamide: Second-gen AR antagonist. Dose: 160 mg daily (four 40 mg capsules). Cost ₹15,000–25,000/month generic. Superior to bicalutamide in progression-free survival.
• abiraterone: CYP17 inhibitor; blocks testosterone synthesis. Dose: 1,000 mg daily with 5 mg prednisone. Cost ₹8,000–15,000/month generic. Requires mineralocorticoid antagonist (eplerenone).
• apalutamide: Next-gen AR antagonist. Dose: 240 mg daily (four 60 mg tablets). Cost ₹20,000–35,000/month. Rapid PSA decline in resistant disease.
• darolutamide: Newest AR antagonist. Dose: 600 mg twice daily. Cost ₹25,000–40,000/month. Non-steroidal, better CNS penetration.

Docetaxel Chemotherapy

When used: Metastatic hormone-sensitive (mHSPC) with PSA >50 or rapid PSA doubling; mCRPC progressing on hormone therapy.

Microtubule stabilizer arrests cell division. Given IV every 3 weeks for 6–10 cycles. STAMPEDE trial showed docetaxel + ADT improved overall survival by 10–12 months in mHSPC vs ADT alone.

Effectiveness: In mHSPC: median overall survival 56 vs 49 months with docetaxel vs control. Median time to progression 20 vs 17 months. In mCRPC: PSA response ~30–45%, median survival 18–19 months.

Side effects: Neutropenia (severe in 30–40%; managed with G-CSF), anemia, thrombocytopenia, neuropathy (feet/hands tingling, 50% with grade 1–2; <10% grade 3), alopecia, mucositis, fatigue. Cardiac toxicity rare. Cumulative neuropathy can be limiting.

Cost in India: Generic docetaxel: ₹15,000–25,000 per 100 mg vial. Full 6-cycle course: ₹1,20,000–2,00,000. Brand (Taxotere): ₹35,000–45,000 per vial.

Cabazitaxel Chemotherapy

When used: mCRPC after progression on docetaxel. Second-line chemotherapy.

Taxane with high oral bioavailability; penetrates BBB. Given IV every 3 weeks for 10 cycles. TROPIC trial showed cabazitaxel improved median overall survival 15.1 vs 12.7 months vs mitoxantrone.

Effectiveness: Median overall survival 15 months in docetaxel-resistant disease. PSA response 35–40%.

Side effects: Similar to docetaxel but may be tolerable after docetaxel resistance. Neutropenia, neuropathy, diarrhea (more frequent), alopecia.

Cost in India: Generic cabazitaxel: ₹20,000–35,000 per 20 mg vial. Course cost ₹2,00,000–3,50,000.

PARP Inhibitors (Olaparib)

When used: mCRPC with BRCA1/BRCA2 or other homologous recombination repair (HRR) mutations (BRCA, ATM, CHEK2, FANCA, etc.). Also used in select non-mutant mCRPC.

Poly(ADP-ribose) polymerase (PARP) inhibitors block single-strand break repair. In HRR-deficient cells, double-strand breaks accumulate and kill cancer. BRCA-mutant cancers are ‘BRCAness’ dependent.

Effectiveness: BRCA-mutant mCRPC: median radiographic progression-free survival 7.4 months (olaparib) vs 3.6 (control). Significant PSA responses. PROfound trial (BRCA-mutant): 51% vs 10% progression-free survival at 12 weeks.

Side effects: Anemia (40%, usually grade 1–2), nausea, fatigue, diarrhea. Secondary malignancy risk ~2–3% over 5 years (lung, gastric). Generally well tolerated.

Cost in India: Olaparib (Lynparza) generic: ₹10,000–20,000 per tablet (300 mg). Daily cost ₹20,000–40,000. Monthly: ₹6,00,000–12,00,000. Genetic testing required first (₹15,000–30,000).

Lu-177 PSMA Therapy

When used: mCRPC PSMA-positive on imaging, after progression through at least one hormone therapy and/or chemotherapy. Salvage therapy before end-of-life.

Lutetium-177 – PSMA-targeting ligand (PSMA-617) delivers beta radiation directly to PSMA-expressing cancer cells. 6 cycles every 6–8 weeks. Theranostic approach: 68Ga-PSMA PET imaging guides patient selection.

Effectiveness: VISION trial (phase 3): median radiographic progression-free survival 8.7 vs 3.7 months (Lu-177 vs control). PSA response >50%: 45% patients. Median overall survival ~15 months in heavily pretreated mCRPC.

Side effects: Bone marrow suppression (anemia 30%, leukopenia 20%; manageable with transfusions/G-CSF), xerostomia (dry mouth, 20%), kidney toxicity (usually grade 1–2; monitor creatinine), secondary malignancy risk ~2–4%. Most tolerable late-line option.

Cost in India: Single cycle Lu-177 PSMA: ₹3,00,000–5,00,000. Six-cycle course: ₹18,00,000–30,00,000. PSMA PET baseline and follow-up: ₹40,000–60,000 per scan. Total treatment cost: ₹22,00,000–35,00,000.

Why Combine Therapies? Hormonal Therapy Rationale

Prostate cancer cells depend on androgens (testosterone and DHT) for growth. Blocking androgen signaling starves the cancer. However, early treatment becomes systemic — we are accepting side effects to prevent possible future spread. The evidence is clearest in two scenarios. First, when cancer has already spread to lymph nodes or bones (metastatic disease at diagnosis), ADT immediately followed by docetaxel chemotherapy has been proven to extend life by 12–18 months compared to ADT alone. This is the standard for metastatic hormone-sensitive prostate cancer. Second, in very high-risk localized disease (Gleason 9–10, PSA >40, or stage T4), adding ADT to radiation therapy improves 10-year survival by 10–15%, preventing progression to incurable metastatic disease. The duration matters: 6 months of ADT is sufficient for intermediate-risk disease combined with radiation, while 24–36 months benefits high-risk patients.

The decision to add docetaxel to ADT hinges on disease burden and PSA kinetics. Men with rapid PSA doubling (doubling time <3 months), very high PSA at diagnosis (>100 ng/mL), or Gleason 8–10 tumors with metastases benefit most. A man with a single bone lesion and PSA 25 might watch with ADT alone; a man with widespread bone involvement and PSA 200 should receive upfront docetaxel – ADT. The STAMPEDE and CHAARTED trials showed median survival gains of 15–20 months with the combination. Cost and toxicity are weighed: docetaxel adds ₹1,50,000–2,50,000 to treatment and causes neuropathy in half of men, but the survival benefit justifies it in appropriate candidates.

Active surveillance versus treatment in localized low-risk disease remains contentious. Tens of thousands of men in India undergo prostatectomy yearly for cancers that would never kill them. Overtreatment wastes resources and causes incontinence, erectile dysfunction, and psychological harm. The PIVOT and ProtecT trials showed surgery and radiation do not improve overall survival in low-risk disease compared to observation, though they reduce 15-year metastasis risk by ~3–5%. Modern practice leans toward initial observation with PSA/DRE monitoring and repeat biopsy at 1–2 years to confirm low-risk status. If Gleason upgrades or PSA accelerates, treatment follows. This strategy spares 60–70% of low-risk men from unnecessary intervention while preserving cure for the 30% who progress.

A Day at HealOnco: Systemic Therapy Timeline

Cost Comparison: Treatment Pathways in India

Our Prostate Cancer Specialists

Our Centres

How Modern Treatment Differs

Weighing Your Options

Active surveillance vs. immediate surgery/radiation Pros Surveillance: Avoids incontinence, erectile dysfunction, and hospitalization in 60–70% who never need treatment. Preserves prostate function. Lower cost. Reduces unnecessary harm. Allows ‘watchful waiting’ for slow-growing cancers. Cons Surveillance: Psychological burden of ‘living with cancer’ for years. Risk of Gleason upgrade on repeat biopsy (10–20%). Requires strict adherence to monitoring. If disease progresses, may require more aggressive salvage therapy. Not suitable if life expectancy >15 years with Gleason 7 or higher. Best for: Very low–low risk, older men (>65 years), PSA <10, Gleason ≤6, fit for compliance and psychological resilience.

Robot-assisted surgery (RARP) vs. radiation (EBRT) Pros Rarp: Single-day curative intervention. Pathological staging confirms margin status and lymph node involvement. Nerve-sparing possible. No long-term radiation damage. Younger men prefer single event. Cons Rarp: Surgical risks: infection, bleeding, anesthesia complications. Incontinence (10–15%), erectile dysfunction (50–70%). Recovery time 4–6 weeks. Pelvic floor rehabilitation needed. Pros Ebrt: Outpatient-based; no surgery. Suitable for elderly/frail. BED to bone higher (less fracture risk). Can treat node involvement without lymph dissection. Cons Ebrt: Late rectal/erectile toxicity (dose-dependent). Cannot assess lymph nodes pathologically. Longer treatment course (8–9 weeks). Small secondary malignancy risk. Best for: RARP: <70 years, fit for surgery, ≤15-year life expectancy, wish to avoid prolonged treatment. EBRT: >70 years, high surgical risk, broad pelvic involvement, patient prefers outpatient approach.

ADT monotherapy vs. ADT – docetaxel in mHSPC Pros Adt Alone: Fewer side effects (no chemotherapy toxicity). Simpler administration. Lower cost (₹2,50,000–4,00,000 vs ₹7,00,000–12,00,000). Cons Adt Alone: Median overall survival 49 months vs 56 months with docetaxel (7-month deficit). Earlier progression. Higher risk of castration-resistant emergence. Pros Docetaxel: Median overall survival 56 months (12–20% improvement). Delays resistance. Better long-term control in Gleason 8–10. Cons Docetaxel: Neutropenia risk (30–40%); potential hospitalizations for fever. Neuropathy (50%), alopecia, fatigue. Cost ₹7,00,000–12,00,000. Cumulative toxicity in elderly. Best for: Docetaxel if: PSA >50, Gleason 8–10, <75 years, excellent performance status (ECOG 0–1). ADT alone if: older, comorbidities, poor bone marrow reserve, or patient decline of chemo.

Hormone therapy escalation: when to add novel agents vs. chemotherapy Consider Novel Hormonal: Abiraterone or enzalutamide have faster PSA kinetics (median time to progression 10–12 months, superior to chemotherapy in this setting). Cost ₹12,00,000–20,00,000/year but covered by many insurances as standard second-line. Consider Chemotherapy: Docetaxel if visceral metastases, rapid doubling time, low PSA only achieved transiently. Median survival 18 months. Cumulative neuropathy limits to 1–2 cycles in many.

ADT side effects: acceptability of hormonal toxicity Side Effect: Hot flashes, weight gain, erectile dysfunction, osteoporosis, gynecomastia. Mitigation: Hot flashes: SSRIs (paroxetine ₹500/month), gabapentin (₹800/month). Weight: dietary counseling, resistance exercise. Erectile: phosphodiesterase-5i (sildenafil ₹2,000/month) or penile rehabilitation protocol. Osteoporosis: baseline DXA, calcium – vitamin D, bisphosphonate if indicated (₹5,000–10,000/injection 6-monthly). Quality Of Life: Most men adapt over 3–6 months. Hot flashes subside in 50% by 2 years. Erectile dysfunction is the most distressing; <40% acceptable without intervention. Informed pre-treatment discussion critical.

Managing Treatment Side Effects

Read the full side effects guide for Prostate Cancer →

What Our Patients Say

Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Frequently Asked Questions

Prostate Cancer Treatment in Top Cities

Prostate Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.

Related Cancers We Treat

Supportive Care at HealOnco

References

1. GLOBOCAN 2022. Cancer Incidence, Mortality and Prevalence Worldwide. WHO International Agency for Research on Cancer. gco.iarc.fr
2. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Tomorrow. World Health Organization International Agency for Research on Cancer. 2020. gco.iarc.fr
3. STAMPEDE Collaborators. Addition of docetaxel, zoledronic acid, or both to standard of care for men with metastatic hormonally sensitive prostate cancer (STAMPEDE): long-term survival results of a randomised controlled trial. Lancet. 2018;391(10136):1908-1920. www.thelancet.com
4. CHAARTED Trial. Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (CHAARTED). N Engl J Med. 2015;373:737-746. www.nejm.org
5. LATITUDE Trial. Fizazi K, Tran N, Fein L, et al. Abiraterone – Prednisone plus Bicalutamide vs. Placebo – Bicalutamide for Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2017;377:352-360. www.nejm.org
6. ENZAMET Trial. Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy for Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2019;381:121-131. www.nejm.org
7. VISION Trial. Sartor O, de Bono JS, Chi KN, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091-1103. www.nejm.org
8. PROfound Trial. de Bono JS, Mehra N, Schroder FH, et al. Olaparib in Metastatic Castration-Resistant Prostate Cancer (BRCA-Mutant) (PROfound). N Engl J Med. 2020;382:2091-2102. www.nejm.org
9. PIVOT Trial. Wilt TJ, Brawer MK, Barry MJ, et al. Prostate Cancer Intervention versus Observation Study (PIVOT). N Engl J Med. 2012;367:203-213. www.nejm.org
10. ProtecT Trial. Donovan JL, Hamdy FC, Lane JA, et al. Patient-Centered Outcomes Research of Treatment for Localized Prostate Cancer (ProtecT). N Engl J Med. 2016;375:1425-1437. www.nejm.org
11. ICMR National Cancer Registry Programme: Incidence and Mortality Estimates. Indian Council of Medical Research. 2023. www.icmr.gov.in
12. American Cancer Society Guideline: Key Statistics for Prostate Cancer. 2025 Updates. https://www.cancer.org/cancer/types/prostate-cancer/about/key-statistics.html www.cancer.org